Press Release
NuGel™ Glycoprotein Enrichment (PBA) Kit Advances Proteomic Study of Glycosylated Synovial Fluid (SF) Proteins
MONMOUTH JUNCTION, NJ, July 1, 2026 –A research team from the Postgraduate Institute of Medical Education and Research in India describes theNuGel™ Glycoprotein Enrichment Kitas an essential method in a proteomic comparison of synovial fluid (SF) from patients with osteoarthritis (OA) and OA co-existing with type 2 diabetes mellitus (OADM). The citation is:
Sharma, A., Saini, U.C., Bhadada, S.K. et al.PBA-enriched glycated/glycosylated synovial fluid proteomic signatures associated with metabolic dysregulation and cartilage degeneration in osteoarthritis with type 2 diabetes.J Transl Med 24, 622 (2026).https://doi.org/10.1186/s12967-026-07984-8
For the discovery-phase analysis, SF samples were processed using theNuGel™ Glycoprotein Enrichment PBA Kit. The pH-dependent attachment of the OH group of boronic acids to the 1,2-cis-diol groups of biomolecules, and the selective presence of these 1,2-cis-diol groups in glycated/glycosylated proteins, formed the basis for the use of NuGel™ PBA-based beads. Next, the enriched samples were analyzed by LC-MS/MS to enable quantitative profiling of cis-diol-containing glycated/glycosylated proteomic alterations associated with OA and OADM. Quantification was performed using DIA-based SWATH-MS.
SWATH-MS profiling revealed substantial proteomic diversity between the two disease conditions. Following rigorous data normalization and statistical analysis, several cis-diol-containing glycation- and glycosylation-enriched proteins were identified as differentially abundant in OADM relative to OA. Among these, HTRA1, CTSG, and AGP1 emerged as the most prominently upregulated proteins, whereas PFN1, GPLD1, PROS1, APOA2, and APOA4 were among the most significantly downregulated.
Collectively, the differential abundance of NuGel™ PBA-enriched, cis-diol-containing, glycation- and glycosylation-associated proteins observed in OADM suggests potential molecular links between diabetes-associated features, such as chronic hyperglycemia and oxidative stress, and heightened inflammatory responses, joint degeneration, and impaired tissue repair. These findings suggest an association between type 2 diabetes mellitus-related metabolic dysregulation, synovial protein glycation/glycosylation, and cartilage degeneration in OADM. Finally, HTRA1, CTSG, and AGP1 emerged as clinically measurable proteins with potential biomarker relevance for distinguishing OADM from OA, which may support improved disease stratification in future studies.
“This is an excellent example of how theNuGel™proprietary passivation technology virtually eliminates non-specific protein-binding sites—making it an ideal silica bead architecture for immobilized-affinity applications such as Phenyl Boronic Acid and other bioseparations. From this foundational surface chemistry, all of ourNuGel™ and NRicher™products are derived,â€� states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.
For more information on theNuGel™ Glycoprotein Enrichment PBA Kit, visit:
For more information about all of our NuGel™-based products, visit:
About Biotech Support Group LLC
Biotech Support Group develops innovative sample preparation technologies that address the emerging needs of proteomics, biomarker discovery, and personalized medicine. Flagship products include Cleanascite™ for lipid removal, AlbuVoid™ and AlbuSorb™ PLUS for serum protein depletion, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low-abundance, family-specific, and targeted proteome enrichment. These products support translational research by simplifying workflows and improving sample quality for downstream analysis.
For Business Development Inquiries:
Matthew Kuruc
Phone: 732-274-2866
Email:[email protected]
Keywords:NuGel™ PBA Kit, Glycation, Glycosylation, LC-MS Proteomics, Mass Spectrometry, Osteoarthritis, Type 2 Diabetes Mellitus, Synovial Fluid Proteome, Glycosylated Proteome, Glycoprotein Enrichment